Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
09 mars 2022 07h00 HE
|
Amryt Pharma plc
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves...
Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules)
08 mars 2022 07h00 HE
|
Amryt Pharma plc
Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules) Data supports a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors...
Results of General Meeting
03 mars 2022 07h00 HE
|
Amryt Pharma plc
Results of General Meeting Share-Repurchase Program Form of Contract and Counterparties Approved DUBLIN, Ireland, and Boston MA, March 3, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage...
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
28 févr. 2022 09h15 HE
|
Amryt Pharma plc
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA DUBLIN, Ireland, and Boston, MA, February 28, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company...
Amryt Supports Rare Disease Day 2022
25 févr. 2022 07h00 HE
|
Amryt Pharma plc
Amryt Supports Rare Disease Day 2022 DUBLIN, Ireland, and Boston MA, February 25, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing...
Amryt to Report FY and Q4 2021 Results on March 9, 2022
23 févr. 2022 07h00 HE
|
Amryt Pharma plc
Amryt to Report FY and Q4 2021 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to...
Amryt Completes $125 Million Non-Dilutive Debt Refinancing
22 févr. 2022 07h00 HE
|
Amryt Pharma plc
Amryt Completes $125 Million Non-Dilutive Debt Refinancing New Facilities Will Significantly Reduce Amryt’s Interest Expense and Cost of Capital and Extend Term Debt Maturity Through 2027 Further...
Notice of General Meeting
01 févr. 2022 07h00 HE
|
Amryt Pharma plc
Notice of General Meeting Amryt seeking shareholder approval for share buybacks and routine matters DUBLIN, Ireland, and Boston MA, February 1, 2022, Amryt Pharma plc (Nasdaq: AMYT), a global,...
Amryt Announces Oleogel-S10 EMA Regulatory Update
28 janv. 2022 07h00 HE
|
Amryt Pharma plc
Amryt Announces Oleogel-S10 EMA Regulatory Update Ad-Hoc Expert Group to provide independent EB specific expertise and advice DUBLIN, Ireland, and Boston MA, January 28, 2022 Amryt (Nasdaq:...
Amryt Announces New Patents for Oleogel-S10
18 janv. 2022 07h00 HE
|
Amryt Pharma plc
Amryt Announces New Patents for Oleogel-S10 DUBLIN, Ireland, and Boston MA, January 18, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...